{"nctId":"NCT00974090","briefTitle":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","startDateStruct":{"date":"2009-09"},"conditions":["Type 2 Diabetes Mellitus"],"count":194,"armGroups":[{"label":"Placebo / Teneli + SU","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)"]},{"label":"Teneli / Teneli + SU","type":"EXPERIMENTAL","interventionNames":["Drug: Teneli / Teneli + SU"]}],"interventions":[{"name":"Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)","otherNames":["MP-513","Amaryl","glimepiride"]},{"name":"Teneli / Teneli + SU","otherNames":["MP-513","Amaryl","glimepiride"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who are 20 - 75 years old\n* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug\n* Patients whose HbA1c is between 7.0% and 10.0%\n* Patients who took Sulfonylurea for diabetes over 12 weeks before administration of investigational drug\n* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)\n* Patients with Class III/IV heart failure symptoms according to NYHA functional classification\n* Patients who are gastrointestinal disorder (diarrhea, vomiting)\n* Patients with serious diabetic complications\n* Patients who are the excessive alcohol addicts\n* Patients with severe hepatic disorder or severe renal disorder\n* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c at Week 12","description":"The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.06"},{"groupId":"OG001","value":"-0.71","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 12","description":"The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"2.2"},{"groupId":"OG001","value":"-17.3","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12","description":"The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.514","spread":"6.072"},{"groupId":"OG001","value":"-65.544","spread":"6.072"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12","description":"The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"4.4"},{"groupId":"OG001","value":"-43.1","spread":"4.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":98},"commonTop":["Nasopharyngitis","Glucose urine present","Protein urine present","Hypoglycaemia","Upper respiratory tract inflammation"]}}}